MediciNova presents interim results from COMBAT-ALS trial of MN-166 for ALS at an international symposium.Quiver AI SummaryMediciNova, Inc. announced that interim analysis results from its Phase 2b/3 COMBAT-ALS...
MediciNova updates shareholders on clinical trials and strategic collaborations for neurodegenerative diseases and inflammatory conditions.Quiver AI SummaryMediciNova, Inc., a biopharmaceutical company...
MediciNova announces patent allowance for MN-001, a method to reduce liver triglyceride synthesis, aiding metabolic disorder treatments.Quiver AI SummaryMediciNova, Inc. has announced that it received...
Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.